Muneerah M Aleissa
Overview
Explore the profile of Muneerah M Aleissa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
82
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kakoullis L, Alonso C, Burns R, Aleissa M, Haddad E, Kim A, et al.
Clin Infect Dis
. 2025 Jan;
PMID: 39873391
Background: Babesiosis poses significant risks of adverse outcomes in individuals with immunocompromising conditions (IC) and asplenia/hyposplenia (AH). This study compares clinical outcomes between these vulnerable groups and immunocompetent patients. Methods:...
2.
Gillett E, Aleissa M, Pearson J, Solomon D, Kubiak D, Dionne B, et al.
Open Forum Infect Dis
. 2024 Nov;
11(11):ofae600.
PMID: 39507879
Background: Current vancomycin monitoring guidelines recommend monitoring 24-hour area under the concentration-time curve (AUC) to minimum inhibitory concentration ratios for patients with serious methicillin-resistant infections. However, there are sparse data...
3.
Alsuhebany N, AlShehri B, Aldairem A, Aleissa M, AlQahtani H, Albarqi K, et al.
Bone Marrow Transplant
. 2024 Apr;
59(7):1043-1045.
PMID: 38627451
No abstract available.
4.
Little J, Dulery R, Shapiro R, Aleissa M, Prockop S, Koreth J, et al.
Transplant Cell Ther
. 2023 Nov;
30(2):233.e1-233.e14.
PMID: 37984797
Post-transplantation cyclophosphamide (PTCy) is an effective strategy for graft-versus-host disease (GVHD) prophylaxis and is the standard of care for haploidentical hematopoietic cell transplantation (HCT). It is increasingly used for matched...
5.
Aleissa M, Little J, Davey S, Saucier A, Zhou G, Gonzalez-Bocco I, et al.
Transplant Cell Ther
. 2023 Mar;
29(6):398.e1-398.e5.
PMID: 36906276
Patients receiving chimeric antigen receptor T cell (CAR-T) therapy may have impaired humoral responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccinations owing to their underlying hematologic malignancy, prior...
6.
Alsowaida Y, Alamer A, Thabit A, Almulhim A, Aleissa M, Kalbasi A, et al.
Am J Health Syst Pharm
. 2023 Jan;
80(8):503-517.
PMID: 36680786
Purpose: Echinocandins are favored drugs for the treatment of fungal infections. There is growing evidence that obese patients treated with echinocandins have lower exposures due to pharmacokinetic (PK) alterations. We...
7.
Aleissa M, Gonzalez-Bocco I, Zekery-Saad S, Kubiak D, Zhang E, Signorelli J, et al.
Open Forum Infect Dis
. 2022 Aug;
9(8):ofac306.
PMID: 35949404
Background: Methicillin-susceptible (MSSA) is a common cause of bloodstream infection (BSI) in patients with febrile neutropenia, but treatment practices vary, and guidelines are not clear on the optimal regimen. Methods:...
8.
Little J, Aleissa M, Beluch K, Gonzalez-Bocco I, Marty F, Manne-Goehler J, et al.
Blood Adv
. 2022 Jul;
6(16):4821-4830.
PMID: 35802461
CAR T-cell therapy has revolutionized the treatment of hematologic malignancies, although its use may be complicated by toxicities, including cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and...
9.
Little J, Shapiro R, Aleissa M, Kim A, Park Chang J, Kubiak D, et al.
Transplant Cell Ther
. 2022 May;
28(8):508.e1-508.e8.
PMID: 35526780
The use of haploidentical donor hematopoietic cell transplantation (haploHCT) has expanded, but recent reports raise concern for increased rates of infectious complications. The incidence and risk factors for invasive fungal...
10.
Gonzalez-Bocco I, Aleissa M, Zhou E, Manne-Goehler J, Koo S, Cheng M, et al.
Open Forum Infect Dis
. 2022 Jan;
9(1):ofab582.
PMID: 34988253
Clarithromycin (CYP inhibitor) can be used instead of azithromycin for nontuberculous mycobacteria therapy in patients requiring CYP substrates to mitigate rifampin's CYP induction. We found no differences in adverse events...